Combotox (Imtox19/Imtox22) / Montefiore Medical Center, National Cancer Institute, Abiogen - LARVOL DELTA

The role of body composition in neurological and hematologic toxicity in a retrospective analysis of 120 breast cancer patients undergoing neoadjuvant chemotherapy: the COMBOTOX study. (PubMed, Breast Cancer Res Treat) - "A routine assessment of BoCo, in addition to evaluation of anthropometric measures and BMI, could allow to personalize chemotherapy doses, in order to reduce chemotherapy-related toxicities."

Journal • Retrospective data • Breast Cancer • Hematological Disorders • Obesity • Oncology • Solid Tumor

Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1; N=10; Completed; Sponsor: Albert Einstein College of Medicine; Recruiting ➔ Completed; N=20 ➔ 10

Enrollment change • Trial completion • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD19 • CD22 • PCR